ReviewCurrent rheumatology reports2018
Induction Therapy for Lupus Nephritis: the Highlights.
Review in Current rheumatology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of tripterygium glycosides tablet for lupus nephritis: a systematic review and Meta-analysis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Pooled it
- Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients.Clinical and experimental immunology · 2020Trial
- Predictive modeling of co-infection in lupus nephritis using multiple machine learning algorithms.Scientific reports · 2024Article
- Clinical research progress of novel biologics for the treatment of lupus nephritis.Clinical and experimental medicine · 2023Review
- Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients.Clinical rheumatology · 2022Article
- Prediction models of treatment response in lupus nephritis.Kidney international · 2022Article
- Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy.Nature reviews. Rheumatology · 2020Review
- Lupus nephritis: challenges and progress.Current opinion in rheumatology · 2019Review
- Individualizing Therapy in Lupus Nephritis.Kidney international reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewLupus nephritis is a frequent complication of systemic lupus erythematosus and is more common and severe in children. This is a disease of the immune system characterized by T cell, B cell, and complement activation, as well as immune complex formation and deposition. The introduction of steroids and later cyclophosphamide transformed lupus nephritis from a fatal to a treatable condition. However, the standard therapies currently used for treatment carry significant toxicity and chronic kidney disease still remains a far too frequent outcome. To address these issues, we will review current and emerging induction therapies in LN. RECENT
findingsSeveral clinical trials have been undertaken to test more effective and safer drugs, often targeting mechanistic disease pathways. At present, it is difficult to identify an induction regimen that is more effective and less toxic than the standard of care; however, we believe continuing efforts in drug development will bring breakthrough agents to clinics.
Indexed as
Identifiers
30109511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.